What are the treatment guidelines for enteric fever (typhoid and paratyphoid) in adults and children, including first‑line regimens, dosing, alternative agents, and management of resistant strains?

Treatment Guidelines for Enteric Fever

Azithromycin 20 mg/kg/day (maximum 1 g) orally for 7 days is the preferred first-line treatment for uncomplicated enteric fever in both adults and children, particularly in regions with high fluoroquinolone resistance. 1, 2

First-Line Treatment Algorithm

For Uncomplicated Cases (Outpatient or Mild Illness)

• Azithromycin 20 mg/kg/day (maximum 1 g/day) orally for 7 days is the WHO-recommended first-line agent, achieving a 94% cure rate and demonstrating 52% lower clinical failure compared to fluoroquinolones (OR 0.48,95% CI 0.26–0.89). 1, 2, 3

• Azithromycin shortens hospital stay by approximately 1 day compared to fluoroquinolones (mean difference −1.04 days, 95% CI −1.73 to −0.34). 1, 3

• Relapse risk is dramatically reduced with azithromycin—91% lower than ceftriaxone (OR 0.09,95% CI 0.01–0.70). 1, 2, 3

• This regimen is safe in pregnancy (FDA Category B) and should be used preferentially over fluoroquinolones, which are contraindicated in pregnant women. 1

For Severe or Hospitalized Cases

• Ceftriaxone 50–80 mg/kg/day (maximum 2 g/day) IV/IM for 5–7 days is the first-line parenteral therapy for patients requiring hospitalization or those with severe illness. 1, 2, 4

• In culture-confirmed cases from Nepal, ceftriaxone reduced treatment failure by 76% compared to gatifloxacin (HR 0.24,95% CI 0.08–0.73). 1, 4

• Ceftriaxone achieves fever clearance approximately 0.52 days faster than azithromycin (mean difference −0.52 days, 95% CI −0.91 to −0.12). 4, 5

• Switch to oral azithromycin once the patient is afebrile for 24 hours and clinically improving, completing a total 7-day course. 2

Special Populations

Infants Under 3 Months

• Ceftriaxone 50–80 mg/kg/day IV is mandatory for all infants younger than 3 months with suspected enteric fever, regardless of clinical severity. 2, 4

• Alternative oral agents lack sufficient safety data in this age group. 4

Children with Neurologic Involvement

• Use ceftriaxone regardless of age to ensure adequate central nervous system penetration. 4

Alternative Agents and Resistance Considerations

When Fluoroquinolones May Be Used

• Fluoroquinolones (ciprofloxacin 500 mg twice daily or ofloxacin 400 mg twice daily for 7 days) should only be used when:

  • Culture confirms nalidixic acid susceptibility and
  • The infection was not acquired from South or Southeast Asia (where resistance exceeds 70–96%). 1, 2

• When susceptibility is confirmed, fluoroquinolones achieve fever clearance in fewer than 4 days with cure rates exceeding 96%. 1

Cefixime: A Less Reliable Option

• Cefixime 8 mg/kg/day (maximum 400 mg) orally for 7–14 days is listed by the American Academy of Pediatrics as an alternative, but carries significant limitations. 2

• Cefixime has a 13-fold higher risk of clinical failure compared to fluoroquinolones (RR 13.39,95% CI 3.24–55.39) and documented failure rates of 4–37.6%. 1, 5

• If cefixime is used, a mandatory test-of-cure at 1 week is required due to high failure rates. 1

• The WHO lists cefixime only as an "alternative" agent, not first-line. 1

Chloramphenicol: No Longer Recommended

• Discontinue empiric use of chloramphenicol, ampicillin, and co-trimoxazole due to widespread multidrug resistance. 2

• Chloramphenicol may be considered only as a last-resort option when no other antibiotics are available. 2

Diagnostic Approach Before Treatment

Blood Culture Timing

• Obtain blood cultures immediately before starting antibiotics in all suspected cases; blood cultures have the highest diagnostic yield (40–80% sensitivity) within the first week of illness. 1, 4

• Stool and urine cultures become positive only after the first week of symptom onset. 1

• Do not use the Widal serologic test—it has inadequate sensitivity and specificity. 1

Management of Septic Patients

• For patients with sepsis features, initiate broad-spectrum antimicrobial therapy immediately after collecting blood cultures—do not delay treatment while awaiting results. 1, 2, 4

• In infants under 3 months with fever, blood cultures are mandatory regardless of other clinical signs. 4

• Narrow therapy to targeted treatment once susceptibility results are available. 2, 4

Monitoring and Expected Response

Fever Clearance Timeline

• Expect fever resolution within 4–5 days of appropriate therapy; mean fever-clearance time with azithromycin is 5.8 days (95% CI 5.1–6.5). 1

• If no clinical improvement by day 5, consider antimicrobial resistance or an alternative diagnosis. 1

Treatment Duration

• Complete the full 7-day course even if fever resolves early—premature discontinuation increases relapse risk, which occurs in 10–15% of inadequately treated cases. 1, 2

• For ceftriaxone, 5–7 days is adequate. 2, 4

Management of Complications

Intestinal Perforation

• Intestinal perforation occurs in 10–15% of patients whose illness exceeds 2 weeks before effective therapy. 1

• Surgical intervention with simple excision and closure achieves an approximately 88% success rate. 1

• For multiple perforations or unhealthy bowel tissue, resection with primary anastomosis is required. 1

Other Severe Complications

• Gastrointestinal bleeding and typhoid encephalopathy also affect 10–15% of patients with prolonged untreated illness. 1

• Reassess fluid and electrolyte balance in patients with persistent symptoms. 2

Common Pitfalls to Avoid

• Never use ciprofloxacin empirically for cases from South or Southeast Asia—resistance rates approach 96% in some regions. 1, 2

• Do not discontinue antibiotics prematurely—complete the full 7-day course even if fever resolves early. 1

• Always modify therapy when susceptibility results become available—empiric regimens should be narrowed based on culture data. 4

• Monitor for QT-prolonging drug interactions when prescribing azithromycin. 1

Adverse Effects

Azithromycin

• Common adverse effects are mild and self-limiting: nausea, vomiting, abdominal pain, and diarrhea. 1, 3

• Monitor for potential QT prolongation, especially with concomitant QT-prolonging medications. 1

Ceftriaxone

• Generally well tolerated with few adverse effects reported in clinical trials. 5

Prevention Strategies

Vaccination

• Typhoid vaccination is recommended for travelers to endemic areas (Latin America, Asia, Africa). 1

• Ty21a oral vaccine: one enteric-coated capsule on alternate days for a total of four capsules, taken with cool liquid ≤37°C, one hour before meals; booster every 5 years. 1

• Parenteral inactivated vaccine: 0.5 mL subcutaneously in two doses spaced ≥4 weeks apart; booster every 3 years. 1

• Vaccines provide only 50–80% protection and do not protect against Salmonella Paratyphi. 1, 2

• Do not use combination typhoid-paratyphoid vaccines—only monovalent S. typhi preparations are recommended due to increased adverse reactions without proven benefit. 1

Hygiene Measures

• Hand hygiene and safe food- and water-handling practices remain essential and cannot be replaced by vaccination. 1, 2